GO:0005068 transmembrane receptor protein tyrosine kinase adaptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005068 describes a molecular adaptor function that physically links transmembrane receptor tyrosine kinases (RTKs) to downstream signaling molecules, enabling coordinated signal transduction [1, 3, 5].
• Adaptor proteins such as Nck and Dok7 exemplify this activity by binding activated RTKs and recruiting effector proteins like Pak1 or MuSK [3, 5].
• This activity is essential for RTK-mediated processes including cell proliferation, differentiation, migration, and survival, and its dysregulation contributes to cancers and neuromuscular disorders [1, 2, 6].
• Key RTKs involved include KIT, FLT3, RET, MuSK, and DDR2, which rely on adaptor-mediated assembly of signaling complexes [1, 4, 6, 8].
• Experimental dissection of GO:0005068 uses knockout, point-mutation, knock-in, and overexpression models combined with phosphoproteomics and imaging [5, 7, 8].
• EDITGENE provides CRISPR-based cell model generation and screening services to study adaptor–RTK interactions in disease-relevant contexts.
Description
Transmembrane receptor protein tyrosine kinase adaptor activity (GO:0005068) is a molecular function that enables a protein to bind a transmembrane receptor tyrosine kinase (RTK) and simultaneously bring one or more other molecules into the same complex, allowing them to function coordinately [1, 3]. This activity is fundamental to RTK signaling because it converts receptor activation into downstream cellular responses by nucleating multiprotein signaling assemblies [3, 5]. Adaptor proteins with this activity often lack catalytic domains but contain modular interaction domains (e.g., SH2, SH3, PTB) that mediate specific protein–protein contacts. For researchers, GO:0005068 provides a conceptual and experimental framework to understand how RTKs such as KIT, FLT3, RET, MuSK, and DDR2 propagate signals and how mutations in adaptors or receptors alter cell behavior [1, 2, 4, 6, 8]. Because dysregulated RTK signaling underlies many cancers and developmental disorders, studying this adaptor activity is critical for identifying therapeutic targets and biomarkers [1, 6].
transmembrane receptor protein tyrosine kinase adaptor activity At A Glance
| GO ID | GO:0005068 |
|---|---|
| GO term | transmembrane receptor protein tyrosine kinase adaptor activity |
| Ontology | molecular_function |
| Synonym | transmembrane receptor protein tyrosine kinase adaptor protein activity; transmembrane receptor protein tyrosine kinase docking protein activity |
| Major function | Binds a transmembrane RTK and one or more other molecules to coordinate signaling complex assembly |
| Example adaptor proteins | Nck, Dok7 (as representative adaptors with this activity) [3, 5] |
| Example RTKs | KIT, FLT3, RET, MuSK, DDR2 [1, 4, 6, 8] |
| Related processes | RTK signaling, cell proliferation, differentiation, migration, survival [1, 2, 6] |
What Is GO:0005068?
According to the Gene Ontology, GO:0005068 (transmembrane receptor protein tyrosine kinase adaptor activity) is the binding activity of a molecule that brings together a transmembrane receptor protein tyrosine kinase and one or more other molecules, permitting them to function in a coordinated way. In other words, it is a non-catalytic scaffolding function that physically bridges an RTK to additional signaling partners, thereby facilitating assembly of a functional signaling complex [1, 3, 5].
Why Is transmembrane receptor protein tyrosine kinase adaptor activity Important in Cell Biology?
GO:0005068 is important because it defines the molecular bridge that allows RTKs to transmit signals to diverse downstream pathways. Without adaptor activity, activated RTKs cannot efficiently recruit and organize effector proteins, leading to defective cellular responses [3, 5]. This function is implicated in normal development and tissue homeostasis, and its perturbation is associated with oncogenesis, tumor progression, and neuromuscular diseases [1, 2, 6]. Understanding this activity therefore informs both basic signal transduction research and the development of targeted therapies [1, 4, 8].
• Enables RTKs to couple to downstream signaling cascades such as MAPK, PI3K/AKT, and cytoskeletal regulators [3, 5].
• Critical for KIT-mediated hematopoiesis, melanogenesis, and germ cell development.
• Required for FLT3 signaling in hematopoietic progenitor cells and implicated in acute myeloid leukemia.
• Essential for RET-mediated neuroendocrine tumorigenesis and developmental disorders.
• Necessary for MuSK activation at the neuromuscular junction, with mutations causing congenital myasthenic syndromes [2, 5].
• Involved in DDR2 signaling in collagen receptor networks and lung cancer mutants.
• Provides a mechanism for signal diversification and specificity through combinatorial adaptor use.
• Dysregulation can lead to aberrant cell proliferation, survival, and migration in cancer [1, 6].
• Represents a potential target for therapeutic intervention in RTK-driven diseases [1, 4].
• Studying adaptor activity helps interpret disease-associated mutations in RTKs and adaptors [5, 8].
Mechanism, Genes and Research Methods
RTK Activation and Adaptor Recruitment
In simple terms: When a growth factor binds its receptor, the receptor turns on and attracts adaptor proteins.
Ligand binding induces dimerization and autophosphorylation of transmembrane RTKs on specific tyrosine residues, creating docking sites for adaptor proteins containing SH2 or PTB domains [1, 4]. For example, activated KIT recruits adaptors that link it to downstream pathways. Similarly, FLT3 activation leads to recruitment of adaptor molecules that propagate signals. This step is the initial event where GO:0005068 activity is engaged.
Assembly of Signaling Complexes
In simple terms: Adaptors act like molecular bridges that bring other proteins together so they can work as a team.
Once bound to the RTK, adaptor proteins use additional interaction domains (e.g., SH3, proline-rich regions) to recruit effector enzymes or scaffold proteins. Nck, for instance, links receptor tyrosine kinases to the serine-threonine kinase Pak1, facilitating coordinated signaling. Dok7 activates MuSK by dimerization and recruitment of downstream components. This assembly is central to GO:0005068 function.
Downstream Signal Propagation
In simple terms: The assembled complex then sends signals inside the cell that change cell behavior.
The adaptor-mediated complex activates downstream cascades such as Ras-MAPK, PI3K-AKT, and Rho-family GTPases, leading to changes in gene expression, cytoskeletal dynamics, and cell fate [3, 5]. In the case of MuSK, Dok7-dependent activation is required for neuromuscular junction formation [2, 5]. RET adaptor interactions drive neuroendocrine tumor cell proliferation.
Negative Regulation and Signal Termination
In simple terms: Cells have brakes to shut down the signal after it has done its job.
Adaptor-mediated signaling is attenuated by phosphatases (e.g., SHP-2) and by endocytosis and degradation of RTK–adaptor complexes [7, 8]. SHP-2 phosphorylation downstream of DDR2 modulates collagen receptor signaling. Endocytosis of RTKs serves as a major mechanism to terminate signaling and recycle receptors. These regulatory steps ensure that GO:0005068 activity is tightly controlled.
Key Genes Involved in GO:0005068 transmembrane receptor protein tyrosine kinase adaptor activity
The following genes encode proteins that either exhibit transmembrane receptor protein tyrosine kinase adaptor activity or are key RTKs and effectors in this process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KIT | RTK that recruits adaptors upon activation | Implicated in gastrointestinal stromal tumors, mastocytosis |
| FLT3 | RTK in hematopoietic progenitors | Mutated in acute myeloid leukemia |
| RET | RTK involved in neuroendocrine tumors | Oncogenic mutations in medullary thyroid carcinoma |
| MUSK | RTK at neuromuscular junction | Mutations cause congenital myasthenic syndromes |
| DOK7 | Adaptor that activates MuSK via dimerization | Mutations cause congenital myasthenia |
| NCK1 | Adaptor linking RTKs to Pak1 | Regulates cytoskeletal dynamics and signaling |
| NCK2 | Adaptor similar to Nck1 | Modulates RTK signaling |
| PAK1 | Serine-threonine kinase recruited by Nck | Effector in RTK-driven cytoskeletal changes |
| DDR2 | Collagen receptor RTK | Mutations in lung cancer; SHP-2 phosphorylation |
| PTPN11 | Phosphatase SHP-2 downstream of DDR2 | Regulates RTK signaling; mutated in cancers |
| GRB2 | Adaptor protein with SH2/SH3 domains | Classic RTK adaptor in Ras-MAPK pathway |
| SHC1 | Adaptor protein binding phosphotyrosine RTKs | Links RTKs to Ras-MAPK |
| GAB1 | Scaffold adaptor for PI3K/AKT | Amplifies RTK signals |
| CRK | Adaptor with SH2/SH3 domains | Regulates cell migration and proliferation |
| CRKL | Adaptor related to CRK | Implicated in leukemias |
| SOS1 | Guanine nucleotide exchange factor recruited by adaptors | Activates Ras downstream of RTKs |
| CBL | E3 ubiquitin ligase adaptor | Negatively regulates RTK signaling via endocytosis |
How Is transmembrane receptor protein tyrosine kinase adaptor activity Regulated?
Adaptor activity at RTKs is regulated by phosphorylation-dependent interactions, competitive binding, and negative feedback loops. SHP-2 (PTPN11) can dephosphorylate RTK docking sites or adaptor proteins, thereby attenuating signaling. Endocytosis and ubiquitination by CBL promote receptor degradation and terminate adaptor-mediated complexes. Additionally, phosphatases and endocytic sorting provide spatial and temporal control of GO:0005068 function [7, 8].
transmembrane receptor protein tyrosine kinase adaptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KIT | Gastrointestinal stromal tumor, mastocytosis | Knockout or point-mutation in cell lines (e.g., GIST-T1) |
| FLT3 | Acute myeloid leukemia | Knock-in of ITD mutation in hematopoietic cells |
| RET | Medullary thyroid carcinoma, Hirschsprung disease | Knockout or point-mutation in neuroendocrine cell lines |
| MUSK | Congenital myasthenic syndrome | Knock-in of patient mutations in muscle cells |
| DOK7 | Congenital myasthenia | Knockout or overexpression in myotubes |
Adaptor Dysfunction in Cancer
Mutations in RTKs or adaptor proteins that mediate GO:0005068 activity can lead to constitutive activation of proliferative and survival pathways. For example, oncogenic KIT mutations in gastrointestinal stromal tumors often bypass normal adaptor regulation. FLT3 internal tandem duplications in acute myeloid leukemia drive ligand-independent activation and adaptor recruitment. RET mutations in medullary thyroid carcinoma lead to aberrant adaptor-mediated signaling. DDR2 mutations in lung cancer alter SHP-2 phosphorylation downstream of collagen receptor networks.
Neuromuscular Junction Disorders
MuSK and its adaptor Dok7 are essential for neuromuscular junction formation. Mutations in DOK7 or MUSK that impair adaptor activity cause congenital myasthenic syndromes characterized by muscle weakness [2, 5]. Dok7-mediated dimerization and activation of MuSK is a critical step where GO:0005068 activity is required.
Developmental and Signaling Disorders
Disruption of adaptor-mediated RTK signaling can affect hematopoiesis, pigmentation, and germ cell development due to KIT signaling defects. Similarly, RET adaptor interactions are critical for enteric nervous system development, and their disruption leads to Hirschsprung disease.
From transmembrane receptor protein tyrosine kinase adaptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of adaptor X impair RTK signaling? | Knockout cell line (e.g., CRISPR KO of DOK7 or NCK1) |
| Does a point mutation in the RTK docking site abolish adaptor binding? | Point-mutation knock-in (e.g., KIT Y568F) |
| Can a tagged adaptor be used to isolate signaling complexes? | Knock-in of epitope-tagged adaptor (e.g., HA-DOK7) |
| Does overexpression of adaptor enhance RTK-driven proliferation? | Overexpression cell line (e.g., NCK1 overexpression) |
| Which genes cooperate with adaptor-mediated RTK signaling? | CRISPR library screening in RTK-dependent cells |
| How does a disease-associated adaptor mutation affect downstream signaling? | Knock-in of patient mutation (e.g., DOK7 mutation) |
How to Study the transmembrane receptor protein tyrosine kinase adaptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Protein–protein interactions | Detect RTK–adaptor binding |
| Phosphoproteomics | Phosphorylation sites and signaling changes | Map downstream pathways of DDR2 mutants |
| FRET/BRET | Real-time protein interactions | Visualize adaptor recruitment to RTKs |
| CRISPR knockout screening | Gene essentiality and synthetic lethality | Identify modifiers of RTK signaling |
| RNA-seq | Transcriptional changes | Assess downstream gene expression upon adaptor loss |
| Proximity ligation assay | In situ protein interactions | Detect adaptor–RTK complexes in fixed cells |
| Endocytosis assays | Receptor internalization and degradation | Study regulation of RTK signaling |
Phosphoproteomics
Phosphoproteomics can identify phosphorylation events downstream of RTK–adaptor complexes. For example, phosphoproteomics of collagen receptor networks revealed SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants. This method helps map signaling nodes regulated by GO:0005068 activity.
Co-immunoprecipitation and Affinity Purification
Co-immunoprecipitation (co-IP) of RTKs or adaptors followed by mass spectrometry can identify binding partners and complex composition. Nck was shown to link RTKs to Pak1 using such approaches. Dok7 was demonstrated to activate MuSK via dimerization using biochemical assays.
Live-Cell Imaging
Fluorescence resonance energy transfer (FRET) and bimolecular fluorescence complementation (BiFC) can visualize RTK–adaptor interactions in real time. Endocytosis of RTKs can be tracked using fluorescently tagged receptors.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that modulate adaptor-mediated RTK signaling. For instance, screens in RTK-dependent cancer cells can reveal synthetic lethal interactions with adaptor proteins [1, 4].
How CRISPR Can Be Used to Study GO:0005068 transmembrane receptor protein tyrosine kinase adaptor activity
Knockout
CRISPR knockout of adaptor genes (e.g., NCK1, DOK7) or RTKs (e.g., KIT, FLT3) can abolish GO:0005068 activity, revealing its role in downstream signaling and cellular phenotypes [1, 3, 5]. Knockout cell lines are valuable for validating adaptor dependence.
Point Mutation
Introducing point mutations in RTK docking sites (e.g., KIT Y568F) or in adaptor binding domains can specifically disrupt adaptor binding without affecting other functions. This helps dissect the precise contribution of GO:0005068 to signaling [1, 5].
Knock-in
Knock-in of epitope tags (e.g., HA, FLAG) into endogenous adaptor loci allows for affinity purification and localization studies. Knock-in of disease-associated mutations (e.g., DOK7 mutations) models congenital myasthenia [2, 5].
Overexpression
Overexpression of adaptor proteins (e.g., NCK1) can amplify RTK signaling and drive oncogenic phenotypes, providing a gain-of-function model to study GO:0005068 activity.
How EDITGENE Supports transmembrane receptor protein tyrosine kinase adaptor activity Research
Researchers studying transmembrane receptor protein tyrosine kinase adaptor activity-related genes often need to determine whether a candidate gene is causally involved in signaling, disease, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for transmembrane receptor protein tyrosine kinase adaptor activity research.
Frequently Asked Questions About transmembrane receptor protein tyrosine kinase adaptor activity
What is transmembrane receptor protein tyrosine kinase adaptor activity?
It is a molecular function (GO:0005068) where a protein binds a transmembrane receptor tyrosine kinase and one or more other molecules, bringing them together to function coordinately [1, 3].
What genes are involved in transmembrane receptor protein tyrosine kinase adaptor activity?
Key genes include adaptors like NCK1, DOK7, and RTKs such as KIT, FLT3, RET, MUSK, and DDR2 [1, 2, 3, 4, 5, 6, 8].
How does GO:0005068 relate to cancer?
Dysregulation of adaptor-mediated RTK signaling can drive oncogenesis, as seen with KIT, FLT3, RET, and DDR2 mutations in various cancers [1, 4, 6, 8].
What diseases are associated with defects in this adaptor activity?
Congenital myasthenic syndromes (MuSK/Dok7), gastrointestinal stromal tumors (KIT), acute myeloid leukemia (FLT3), and medullary thyroid carcinoma (RET) [1, 2, 4, 5, 6].
Which experimental methods are used to study GO:0005068?
Co-immunoprecipitation, phosphoproteomics, FRET, CRISPR screening, and endocytosis assays are commonly used [3, 7, 8].
What is the role of Dok7 in MuSK signaling?
Dok7 activates MuSK via dimerization, a process essential for neuromuscular junction formation.
How does Nck link RTKs to downstream effectors?
Nck binds activated RTKs and recruits Pak1, connecting them to cytoskeletal signaling.
Can CRISPR knockout help study adaptor activity?
Yes, knockout of adaptor genes or RTKs abolishes GO:0005068 activity, revealing its role in signaling and disease [1, 3, 5].
What is the difference between adaptor and scaffold proteins?
Adaptors typically lack catalytic activity and mediate protein–protein interactions, while scaffolds may also localize signaling components; GO:0005068 specifically describes adaptor activity for RTKs [1, 3].
How is RTK adaptor signaling terminated?
Endocytosis and phosphatases such as SHP-2 attenuate signaling by dephosphorylating components or promoting receptor degradation [7, 8].
Conclusion
GO:0005068 transmembrane receptor protein tyrosine kinase adaptor activity is a central molecular function that enables RTKs to assemble functional signaling complexes. Through adaptor proteins like Nck and Dok7, RTKs such as KIT, FLT3, RET, MuSK, and DDR2 transmit signals that control cell proliferation, differentiation, and migration [1, 2, 3, 4, 5, 6, 8]. Dysregulation of this activity contributes to cancers and neuromuscular disorders, making it a compelling area for basic and translational research [1, 2, 6]. EDITGENE offers comprehensive CRISPR services to create knockout, point-mutation, knock-in, and overexpression models, as well as library screening and bioinformatics support, to accelerate discoveries in this field.
References
- 1. Roskoski R Jr. 2005. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.. Biochem Biophys Res Commun 337(1):1-13 PMID: 16129412
- 2. Herbst R. 2020. MuSk function during health and disease.. Neurosci Lett 716:134676 PMID: 31811897
- 3. Galisteo ML et al.. 1996. The adaptor protein Nck links receptor tyrosine kinases with the serine-threonine kinase Pak1.. J Biol Chem 271(35):20997-1000 PMID: 8798379
- 4. Drexler HG et al.. 2004. FLT3: receptor and ligand.. Growth Factors 22(2):71-3 PMID: 15253381
- 5. Bergamin E et al.. 2010. The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization.. Mol Cell 39(1):100-9 PMID: 20603078
- 6. Ichihara M et al.. 2004. RET and neuroendocrine tumors.. Cancer Lett 204(2):197-211 PMID: 15013219
- 7. Goh LK et al.. 2013. Endocytosis of receptor tyrosine kinases.. Cold Spring Harb Perspect Biol 5(5):a017459 PMID: 23637288
- 8. Iwai LK et al.. 2013. Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants.. Biochem J 454(3):501-13 PMID: 23822953
